A previous study has reported that HIF-1α inhibition provides adjuvant immune activity, thereby improving the efficacy of tumor antigen-based DC vaccines by augmenting the proliferation and function of cytotoxic T lymphocytes and increasing IFN-γ production in a breast cancer model [26]. Here, IFNG is linked to neoplasm.